Despite scientific discoveries in the field of gene and cell therapy, some diseases still have
no effective treatment. Advances in genetic engineering methods have enabled the …

CRISPR-based drugs can theoretically manipulate any genetic target. In practice, however,
these drugs must enter the desired cell without eliciting an unwanted immune response, so …

Recent advancements in gene supplementation therapy are expanding the options for the
treatment of neurological disorders. Among the available delivery vehicles, adeno …

The discovery of naturally occurring adeno-associated virus (AAV) isolates in different
animal species and the generation of engineered AAV strains using molecular genetics …

The glycan chains of vertebrate glycoconjugates are composed mostly of five-and six-
carbon sugars. One striking exception is the family of sialic acids (Sia), which are R-keto …

Adeno-associated virus (AAV) is the leading vector in emerging treatments of inherited
diseases. Higher transduction efficiencies and cellular specificity are required for broader …

Recombinant adeno-associated viral (AAV) vectors have rapidly advanced to the forefront of
gene therapy in the past decade. The exponential progress of AAV-based vectors has been …

Sialic acid linked to glycoproteins and gangliosides is used by many viruses as a receptor
for cell entry. These viruses include important human and animal pathogens, such as …

Adeno-associated virus (AAV) entry is determined by its interactions with specific surface
glycans and a proteinaceous receptor (s). Adeno-associated virus receptor (AAVR)(also …

Neurological disorders affecting the central nervous system (CNS) are still incompletely
understood. Many of these disorders lack a cure and are seeking more specific and effective …